Tau phosphorylation at pS199 and pT231 has been implicated in AD neuropathology, which provides a possible target for the development of anti-tau agents that could potentially attenuate AD-related pathologies [13,16]. The gene discussed is MAPT; the disease is Alzheimer disease.